Moderna stock rises after RSV vaccine shown to be 83% effective in older adults

Moderna says its RSV vaccine highly effective in older adultsПодробнее

Moderna: RSV vaccine is 84% effective in older adultsПодробнее

Moderna stock rises on Q1 earnings, positive vaccine guidanceПодробнее

Moderna stock rises after analyst upgrade, price target raiseПодробнее

Moderna shares up after hiking forecast on Covid-19 vaccineПодробнее

Moderna's mRNA RSV vaccine propels stock gainsПодробнее

Moderna successful trials for RSV vaccineПодробнее

Moderna's phase three RSV trial found to be 83.7% effective in older adultsПодробнее

Moderna announces successful trials for RSV vaccineПодробнее

What to know about older adults and the RSV vaccineПодробнее

Moderna stock rises on positive results in flu vaccine trialПодробнее

Moderna and Merck’s cancer vaccine trial shows promising initial resultsПодробнее

Moderna stock up after upgrade to Buy from NeutralПодробнее

Moderna prepares to submit RSV vaccine for FDA approvalПодробнее

Moderna: RSV vaccine about 84% effective at preventing serious illnessПодробнее

RSV vaccine for older adults possible later this year - Medical MinuteПодробнее

Moderna CEO: We're preparing our FDA filing for our RSV vaccineПодробнее

RSV Illness Vaccination BenefitsПодробнее

Pfizer: Trials show RSV vaccine is more than 85% effective for older adultsПодробнее